

Appl. No. 09/724,575  
Amdt. Dated May 15, 2003  
Reply to Office Action of December 12, 2002

PATENT

AMENDMENTS TO THE SPECIFICATION:

Please amend the paragraph beginning on page 25, line 23 as follows:

By way of example, as described above, the therapeutic agent used in treating Alzheimer's disease or other amyloid diseases characterized by A $\beta$  fibril deposition can be any of the naturally occurring forms of A $\beta$  peptide, and particularly the human forms (i.e., A $\beta$ 39, A $\beta$ 40, A $\beta$ 41, A $\beta$ 42 or A $\beta$ 43). The sequences of these peptides and their relationship to the APP precursor are known in the art and are well known in the art (*e.g.*, Hardy et al., TINS 20, 155-158 (1997)). For example, A $\beta$ 42 has the sequence:

H2N-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-  
Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-  
Gly-Val-Val-Ile-Ala-OH. (SEQ ID NO: ~~1~~ 34)

Please enter the enclosed paper copy of the Sequence Listing, pages 1-11, at the end of the application.